Zytiga 250mg

Zytiga is an anti-androgen that inhibits the growth and development of prostate cancer cells. The drug is effective for the treatment of inoperable and metastatic tumors.

The pill has a convex oval shape. The pill has an engraving on the surface. The active substance of the drug is abiraterone acetate. The auxiliary ingredients include cellulose, povidone and sodium lauryl sulfate.

The main mechanism of action of the drug is the reduction of testosterone level in blood plasma. Moreover, the drug has an analgesic effect. During the clinical trials, the patients who received therapy with Zytiga didn’t experience the pain syndrome and had a prolonged analgesic effect from the drug. The defects of bone/cartilage and bone fractures appeared more rarely.

Main indication for use of Zytiga is a metastatic castration-resistant prostate cancer. It is used in combination with prednisolone.

Contraindications:

hypersensitivity to the drug components;
children;
liver- kidney dysfunction;
lactose intolerance;
cardiovascular disorders (increased blood pressure and myocardial infarction in history).

As the drug has a teratogenic effect, you should use contraceptives during the treatment.
The use of Zytiga can cause a number of side effects, such as hypertension and cardiac abnormalities, as well as haematuria and infectious diseases. On the part of musculoskeletal system, it can cause fractures.

You should take the drug before/2 hours after the meal. Take 4 pills at a time (you shouldn’t chew the pills or take them with water).

Standard treatment course should be completed with the use of prednisolone (10 mg a day). The duration of treatment must be defined by your doctor. During the treatment, you should control the level of bilirubin and potassium electrolytes in blood plasma and the amount of free fluid in the body.
If you skipped one pill, take it the next day. Never take the double dose of the drug.

Patients with kidney and liver dysfunctions should take the drug with caution. Don’t take the medication if you have severe liver/kidney failure.

In case of any violations in the blood counts, the therapy should be stopped until their normalization. The next courses should be conducted under the control of your physician, and the dose should lower than standard. If the blood counts keep worsening, the treatment should stop.